Skip NavigationSkip to Content
CANCER IMMUNOLOGY AND IMMUNOTHERAPY:
From Conception to Delivery


October 12th - 13th, 2017
Top Right Header
Spacer image Spacer
Spacer CANCER IMMUNOLOGY AND IMMUNOTHERAPY: From Conception to Delivery - Agenda

Agenda

Thursday, October 12th


Introductions

08:20 a.m. Tom Misteli, Director, Center for Cancer Research, National Cancer Institute

Session I: The Basis of Tumor Recognition
       Chair: Larry Samelson
08:30 a.m. James P. Allison (MD Anderson)
"Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities"
09:00 a.m. Nicholas P. Restifo (National Cancer Institue)
"Basic principles of cancer immunotherapy"
09:30 a.m. Steven Rosenberg (National Cancer Institute)
"Cell targeting of unique cancer mutations: A general approach to the immunotherapy of metastatic cancer"
10:00 a.m. Robert Schreiber (University of Washington, St. Louis)
"Cancer Neoantigens as Targets for Natural and Therapeutic Anti-Tumor Responses"
10:30 a.m.

Break



Session II: Checkpoint Modulators
        Chair: James Gulley
11:00 a.m. Jedd Wolchok (Memorial Sloan Kettering)
"Immune Checkpoint Blockade: blurring the line between autoimmunity and tumor immunity"
11:30 a.m. Suzanne Topalian (Johns Hopkins University School of Medicine)
"PD-1 blockade: a common denominator for cancer therapy"
12:00 p.m. Antoni Ribas (University of California, Los Angeles)
"Overcoming resistance to PD-1 blockade therapy"
12:30-1:45 p.m.

Lunch and Poster Session



Session III: Fundamentals of CAR-based Therapies I
         Chair: Dinah Singer
01:45 p.m. Malcolm Brenner (Texas Children's Hospital)
"CARS versus TCRs for the treatment of malignant disease"
02:15 p.m. Michel Sadelain (Memorial Sloan Kettering)
"CARs beyond CD19: new targets and new T cells"
02:45 p.m. Carl June (University of Pennsylvania)
"Engineering T cells for cancer therapy"
03:15 p.m.

Break



Session IV: Fundamentals of CAR-based Therapies II
         Chair: Luca Gattinoni
03:45 p.m. Stanley Riddell (Fred Hutchinson Cancer Research Center),
"Strategies for enhancing CAR T cell efficacy in hematologic malignancies and solid tumors"
04:15 p.m. James Kochenderfer (National Cancer Institute)
"Chimeric antigen receptor T-cell therapy for hematologic malignancies"
04:45 p.m. Crystal Mackall (Stanford University)
"Using CAR T Cells to Probe T Cell Exhaustion"


Friday, October 13th

Session V: The Basis of Tumor Recognition II
        Chair: Tim Greten
08:30 a.m. Ira Mellman (Genentech)
"The mechanistic basis of cancer immunotherapy"
09:00 a.m. Tyler Jacks (Massachusetts Institute of Technology)
"Genetic engineering meets tumor immunology: Lessons from mouse models of cancer"
09:30 a.m. Ton Schumacher (Netherlands Cancer Institute)
"T cell recognition of human cancer"
10:00 a.m.

Break



Session VI: Fundamental Biology of T Lymphocytes
          Chair: Jay Berzofsky
10:30 a.m. "To be determined"
11:00 a.m. Thomas Waldmann (National Cancer Institute)
"Bringing IL-15 to therapeutic fruition in combination therapy with anti-cancer monoclonal antibodies to increase their ADCC and efficacy"
11:30 a.m. Ira Pastan (National Cancer Institute)
"Immunotoxins Synergize with CTLA-4 Blockade to Eradicate Murine Cancer by Promoting Anticancer Immunity"
12:00 p.m.

Lunch and Poster Session



Session VII: Cancer Vaccines and their Context
          Chair: James Yang
02:00 p.m. Ugur Sahin (Johannes Gutenberg University Mainz)
"mRNA based Cancer immunotherapy"
02:30 p.m. Jeffrey Schlom (National Cancer Institute)
"Combinatorial Immunotherapies"
03:00 p.m. Tom Gajewski (University of Chicago)
"Immune system/tumor cell/host interactions and immunotherapy efficacy"
03:30 p.m. Laurence Zitvogel (Gustave Roussy)
"Boundaries between the gut microbiome and the tumor microenvironment"
04:00 p.m.

Poster Session


05:30 p.m.

Adjourn


General Information

For conference related questions please contact:

Julia Lam
301-846-6957

Kathy Easterday
301-846-5763

Location

Masur and Lipsett Auditorium, Blg 10
NIH - Bethesda, MD

Spacer Image
Bottom Conference Border